Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06291818 · ClinicalTrials.gov registry record · NA
Self-Adhering Magnetic Device to Treat Corneal Exposure
A NA study of Paralytic Lagophthalmos and Corneal Exposure, sponsored by University of Illinois at Chicago.
- Recruiting
- Registry status
- NA
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT06291818: Recruiting NA study of Paralytic Lagophthalmos and Corneal Exposure, sponsored by University of Illinois at Chicago.
NCT06291818 is a NA study of Paralytic Lagophthalmos and Corneal Exposure that is actively recruiting participants, run by University of Illinois at Chicago. The registered enrollment target is 25 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06291818, a NA study of Paralytic Lagophthalmos and Corneal Exposure, is actively recruiting participants, sponsored by University of Illinois at Chicago.
- RECRUITING
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
Paralytic lagophthalmos can be difficult to treat and manage. It has a host of causes and effects, one of which (for the latter) is exposure keratopathy. Untreated, this can lead to corneal ulceration, inflammation, and potentially blindness. Despite a variety of attempts at treating this complex condition, none have satisfactorily reduced complications ranging from ease of use to aesthetics. With improvement in magnetic technology, however, that may change. Barmettler et al (2014) have demonstrated preliminary success of externally affixed magnets in closing both model and patient eyelids. As such, we hypothesize that magnetic devices can be used to treat corneal exposure by controlling eyelid position.
Primary Outcome
Use of a temporary magnetic system for tarsorrhaphy (MST) to provide adequate closure of the eyes for ultimate use in conditions causing lagophthalmos (a disorder in eyelid closure)
Conditions Studied
Interventions
- DEVICE temporary magnetic system for tarsorrhaphy (MST)
Study Locations (1)
Illinois
- University of Illinois - Specialty Care Building - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2024-04-17 |
| Est. Completion | 2025-04-01 |
| Phase | NA |
What NCT06291818 shows while recruiting
NCT06291818 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Paralytic Lagophthalmos appearing as the primary indexed condition, and to 1 intervention - of which temporary magnetic system for tarsorrhaphy (MST) is the first listed.
NCT06291818 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06291818 about?
NCT06291818 is a clinical study titled "Self-Adhering Magnetic Device to Treat Corneal Exposure". Paralytic lagophthalmos can be difficult to treat and manage. It has a host of causes and effects, one of which (for the latter) is exposure keratopathy. Untreated, this can lead to corneal ulceration, inflammation, and potentially blindness. Despite a variety of attempts at treating this complex co...
What is the current status of trial NCT06291818?
This trial is currently recruiting. It is a NA study. The enrollment target is 25 participants. The study started on 2024-04-17. Estimated completion is 2025-04-01.
What conditions does trial NCT06291818 study?
This clinical trial studies the following conditions: Paralytic Lagophthalmos, Corneal Exposure.
What interventions are being tested in trial NCT06291818?
The interventions under investigation include: temporary magnetic system for tarsorrhaphy (MST) (DEVICE).
Who is sponsoring clinical trial NCT06291818?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06291818 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06291818's enrollment target sits among peer trials
25 1713th of 2000 higher than 265 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI